Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read General business news Can Illumina’s SomaLogic takeover finally make multiomics scalable at pharma speed? Illumina has acquired SomaLogic to deepen its proteomics and multiomics capabilities. Find out what this means for genomics, pharma, and platform rivals. byPallavi MadhirajuFebruary 2, 2026